In context
Ziconotide is a specialised medicine for severe chronic pain. The US-labelled product Prialt is used when intrathecal therapy is warranted and other treatments are inadequate or not tolerated. [1]
At a glance
- Type
- Peptide medicine
- Regulatory context
- United States: Prialt is labelled for severe chronic pain in adults who meet the specified treatment criteria.
- Evidence
- The label addresses a specialised pain-treatment setting. It is not evidence for general wellness use.
How it is classified
Ziconotide blocks N-type calcium channels. Its place in medicine illustrates why the word peptide alone says very little about a substance's use or safety. [1]
Why context matters
The Prialt indication concerns severe chronic pain with specific prior-treatment limitations. It does not support using ziconotide for routine pain, recovery or performance. [1]
Safety and clinical context
This is specialised intrathecal treatment, not a consumer injection or self-treatment option. Product-specific warnings and clinical supervision are essential.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- Prialt — US prescribing information dailymed.nlm.nih.gov